New Weight Loss Drug May Offer Fewer Gastrointestinal Side Effects

A recent study conducted by researchers at the University of Pennsylvania School of Nursing suggests that tirzepatide, a promising medication for weight management, might cause fewer side effects like nausea and vomiting compared to the commonly used drug semaglutide. Published in Science Advances, this research utilized preclinical models to assess the efficacy and tolerability of these drugs. Both medications were effective in decreasing food intake and reducing overall body weight. However, tirzepatide demonstrated a significant advantage in side effect profile, likely due to its dual mechanism of action. It targets both GLP-1 and GIP receptors, whereas semaglutide primarily acts on GLP-1 receptors. The inclusion of the GIP receptor appears to help mitigate adverse gastrointestinal effects, which are common hurdles in obesity treatments.

Dr. Bart C. De Jonghe, a Professor of Nutrition involved in the study, expressed optimism about the findings, indicating that tirzepatide's ability to engage two metabolic pathways could lead to more tolerable options for patients battling obesity and diabetes. The development of such medications aims to improve patient adherence by minimizing side effects while maintaining effectiveness in weight loss. These insights highlight ongoing advancements in pharmacotherapy for obesity, emphasizing the need for treatments that are both effective and comfortable for patients.